Alaunos Therapeutics Q3 2026 Results: Net Loss of $772K, Loss Narrows
Alaunos Therapeutics reported a net loss of $2.7 million for the nine months ended September 30, 2026, as it transitioned from TCR therapies to pulmonary arterial hypertension treatments. The company's cash position decreased to $615,000, and it recently acquired Velaris Therapeutics in October 2026 to bolster its pipeline.
- Key figure
- Net loss $772K